Without effective collaboration between your R&D and IP teams, critical protection can be compromised, risks can increase, and the potential for successful commercialisation can be diminished.
Managing conflicts between scientific innovation and patentability requires a careful balance between pushing the boundaries of scientific discovery and meeting the rigid legal criteria for obtaining a patent.
Whether your organisation is focused on discovering new therapeutics, developing generics, or exploring drug repurposing, the latest whitepaper by CAS – Synergizing Innovation and Protection – outlines how this synergy must span the entire drug development process. From initial investment planning and target identification to clinical development and commercialisation, alignment is essential.
Download this special report to discover seven leading strategies to boost the critical partnership between your IP and R&D teams today
